Skip to main content
      New research presented this week at ACR  Convergence, the American College of  Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a patient’s drug serum levels are regularly assessed to adjust the dose and intervals, 
      New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017. (Abstract #1783).
      Drug development in the USA: Did you know?
      1. Typical drug development timeline is 10-15 years;
      2. It cost as much as U

      Dr. John Cush RheumNow

      4 years ago
      Drug development in the USA: Did you know? 1. Typical drug development timeline is 10-15 years; 2. It cost as much as US $2.6 billion to bring a drug to market; 3. Only 0.02% of drugs in development make it to market https://t.co/GXKddBLOUv
      New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine (
      #ACR21 is nearly here and we want to see your best images of learning virtually, missing a meeting in San Francisco, wel

      Dr. John Cush RheumNow

      4 years ago
      #ACR21 is nearly here and we want to see your best images of learning virtually, missing a meeting in San Francisco, wellness, or break time activities. Tweet your pic and make sure to include #RheumPix and #ACR21 and we’ll RT our favorites. https://t.co/R5mCpsuMye
      Sign up today to receive #ACR21 news and select topic emails throughout the conference. #RheumNow

      https://t.co/riyAnrRH

      Dr. John Cush RheumNow

      4 years ago
      Sign up today to receive #ACR21 news and select topic emails throughout the conference. #RheumNow https://t.co/riyAnrRHhX https://t.co/XzgOL16X0D
      Nice JRheum Editorial by Jeff Sparks, Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door; sp

      Dr. John Cush RheumNow

      4 years ago
      Nice JRheum Editorial by Jeff Sparks, Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door; speaks to the total burden of morbididy in Chronic disease. RA has more morbidity, that leads to more mortality @jeffsparks https://t.co/s5spRLvXrm https://t.co/yvweR3AZd2
      ×